βIII-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer.

e15174 Background: Docetaxel is a tubulin-targeting cytotoxic that remains first-line therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) even though half of pts are rep...